查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1747731

现实世界数据的全球市场

Real World Data
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球真实世界数据市场规模将达到 54 亿美元

全球现实世界数据市场规模预计在2024年为22亿美元，预计到2030年将达到54亿美元，2024年至2030年的复合年增长率为15.9%。报告分析的细分市场之一「服务组件」预计复合年增长率为17.7%，到分析期结束时将达到37亿美元。资料集组件细分市场在分析期间内的复合年增长率预计为12.5%。

美国市场规模估计为 5.905 亿美元，中国市场预计复合年增长率为 14.9%

美国现实世界数据市场规模预计在2024年达到5.905亿美元。预计到2030年，作为世界第二大经济体的中国市场规模将达到8.354亿美元，在2024-2030年的分析期内，复合年增长率将达到14.9%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为14.8%和13.5%。在欧洲，预计德国市场的复合年增长率将达到11.4%。

全球「真实世界数据」市场—主要趋势与驱动因素摘要

现实世界的数据会重塑基于证据的决策的未来吗？

真实世界数据 (RWD) 正在成为医疗创新的基石，将临床研究范式从受控临床试验转变为从真实世界患者体验中提取的证据。来自电子健康记录(EHR)、保险理赔、病患登记、穿戴式装置和行动医疗应用程式的 RWD 能够洞察不同族群的治疗效果、安全性、依从性和疗效。这使得监管机构、付款人和製药公司能够了解治疗在受控环境之外的效果，从而支持自适应临床试验、药物安全检测和基于价值的报销模式。在公共卫生领域，RWD 可以为政策决策提供信息，并即时追踪病情进展。随着医疗保健系统推动个人化、数据主导的医疗服务，RWD 正在成为一种策略性资产，将患者行为与可操作的临床洞察联繫起来。

什么技术可以最大程度发挥 RWD 的潜力？

健康数据的爆炸性增长和数据分析技术的进步正在释放现实世界数据利用的新领域。云端运算、巨量资料平台和人工智慧演算法正在实现对大量不同资料集的提取、协调和即时分析。自然语言处理 (NLP) 从临床记录和非结构化 EHR 资料中提取结构化见解。 HL7 FHIR 等互通性框架正在改善跨系统和相关人员的资料共用。人们正在探索使用区块链来确保数据来源、安全性和患者同意。这些技术正在将 RWD 从被动记录转变为推动药物开发、人口健康策略和个人化治疗途径的动态资源。随着资料生态系统的成熟，RWD 的品质、可靠性和监管可接受性也在不断提高。

整个医疗生态系统的相关人员如何接受 RWD？

製药公司正在将 RWD 纳入药物生命週期的所有阶段，从临床试验设计和地点选择到上市后监测和标籤扩展。 FDA 和 EMA 等监管机构越来越依赖 RWD 来支持核准和监测真实世界人群的安全性。付款人正在使用 RWD 来评估成本效益和确定覆盖范围。医疗保健提供者正在应用 RWD 分析来改善护理协调、减少医院再入院率和优化治疗通讯协定。患者也正在成为关键的相关人员，他们透过应用程式和穿戴式装置提供数据，并要求透明度和控制力。围绕 RWD 的相关人员利益的融合正在促进伙伴关係、数据联盟和创新中心，加速将健康数据转化为健康影响。

什么推动了全球现实世界数据市场的成长？

现实世界数据市场的成长得益于健康数据基础设施的进步、监管支持以及最终用户对个人化、基于价值的护理的需求。从技术上讲，改进的分析工具、云端扩充性和互通性标准使我们能够从庞大且多样化的资料集中获取切实可行的见解。从最终用户的观点来看，生物製药公司、付款人和医疗系统正在利用 RWD 来提高效率、优化结果并满足不断变化的护理期望。数位健康工具、穿戴式装置和病人参与平台的使用增加正在产生更丰富的数据集以供分析。监管机构在决策和政策制定中支持 RWD 的努力也增加了市场的可信度。随着全球医疗保健系统从数量转向价值，从现实世界证据中获得有意义见解的能力正在成为关键的竞争优势。

部分

组件（服务、资料集）；应用（药物开发和核准、市场准入和报销/研究资格、上市后监测、临床研究、其他应用）；最终用途（製药和医疗设备公司、付款人、医疗保健提供者、政府机构、其他最终用途）

受访企业范例（共42家）

  • Aetion, Inc.
  • Atropos Health
  • BEKHealth
  • Cerner Corporation
  • Clarify Health Solutions
  • ConcertAI
  • Datavant
  • Evidera, Inc.
  • Flatiron Health, Inc.
  • HealthVerity
  • IBM Corporation
  • ICON plc
  • IQVIA Holdings Inc.
  • K2view
  • Merative
  • Mount Sinai Health System
  • Optum, Inc.
  • Palantir Technologies Inc.
  • PAREXEL International Corporation
  • SAS Institute Inc.

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口（成品和原始OEM）来预测其竞争地位的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括人为提高销货成本、盈利下降、供应链重组以及其他微观和宏观市场动态。

全球产业分析师密切关注来自全球顶尖首席经济学家（14,949位）、智库（62家）以及贸易和产业协会（171家）的专家的意见，以评估其对生态系统的影响并应对新的市场现实。我们追踪了来自每个主要国家的专家和经济学家对关税及其对本国影响的看法。

全球产业分析师预计，这场动盪将在未来2-3个月内逐渐平息，新的世界秩序将更加清晰地建立。全球产业分析师正在即时追踪这些事态发展。

2025年4月：谈判阶段

在4月的报告中，我们将探讨关税对全球整体市场的影响，并提供区域市场调整。我们的预测是基于历史数据和不断变化的市场影响因素。

2025年7月：最终关税调整

在各国宣布最终重置后，客户将在 7 月收到免费更新，最终更新将包含明确的关税影响分析。

相互和双边贸易及关税影响分析：

美国<>中国<>墨西哥<>加拿大<>欧盟<>日本<>印度<>其他176个国家

领先的产业经济学家：全球产业分析师知识库追踪了 14,949 位经济学家，其中包括来自民族国家、智库、贸易和产业协会、大型企业以及各领域专家的最具影响力的首席经济学家，他们共用了这场前所未有的全球经济状况模式转移的影响。我们超过 16,491 份报告大多遵循基于里程碑的两阶段发布计划。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 竞赛

简介目录
Product Code: MCP35640

Global Real World Data Market to Reach US$5.4 Billion by 2030

The global market for Real World Data estimated at US$2.2 Billion in the year 2024, is expected to reach US$5.4 Billion by 2030, growing at a CAGR of 15.9% over the analysis period 2024-2030. Services Component, one of the segments analyzed in the report, is expected to record a 17.7% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Datasets Component segment is estimated at 12.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$590.5 Million While China is Forecast to Grow at 14.9% CAGR

The Real World Data market in the U.S. is estimated at US$590.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$835.4 Million by the year 2030 trailing a CAGR of 14.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.8% and 13.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.4% CAGR.

Global "Real World Data" Market - Key Trends & Drivers Summarized

Is Real World Data Reshaping The Future Of Evidence-Based Decision Making?

Real World Data (RWD) is becoming a cornerstone of healthcare innovation, shifting the paradigm from controlled clinical trials to evidence drawn from real-life patient experiences. Sourced from electronic health records (EHRs), insurance claims, patient registries, wearables, and mobile health apps, RWD provides insights into treatment efficacy, safety, adherence, and outcomes across diverse populations. It allows regulators, payers, and pharmaceutical companies to understand how therapies perform outside controlled environments, supporting adaptive clinical trials, pharmacovigilance, and value-based reimbursement models. In public health, RWD informs policy decisions and tracks disease progression in real-time. As healthcare systems push for personalized, data-driven care, RWD is emerging as a strategic asset that links patient behavior with actionable clinical insights.

What Technologies Are Unlocking The Full Potential Of RWD?

The explosion of health data and advances in data analytics are unlocking new frontiers for Real World Data utilization. Cloud computing, big data platforms, and AI algorithms are enabling the ingestion, harmonization, and real-time analysis of massive, heterogeneous datasets. Natural language processing (NLP) is extracting structured insights from clinical notes and unstructured EHR data. Interoperability frameworks like HL7 FHIR are improving data sharing across systems and stakeholders. Blockchain is being explored to ensure data provenance, security, and patient consent. These technologies are transforming RWD from passive records into dynamic resources that fuel drug development, population health strategies, and personalized treatment pathways. As data ecosystems mature, the quality, reliability, and regulatory acceptance of RWD are also improving.

How Are Stakeholders Across The Healthcare Ecosystem Embracing RWD?

Pharmaceutical companies are integrating RWD into all stages of the drug lifecycle-from trial design and site selection to post-market surveillance and label expansion. Regulators like the FDA and EMA are increasingly relying on RWD to support approvals and monitor safety in real-world populations. Payers are using RWD to assess cost-effectiveness and inform coverage decisions. Healthcare providers are applying RWD analytics to improve care coordination, reduce readmissions, and optimize treatment protocols. Patients are also becoming key stakeholders, contributing data through apps and wearable devices while demanding transparency and control. The convergence of stakeholder interests around RWD is fostering partnerships, data consortiums, and innovation hubs that accelerate the transformation of health data into health impact.

What’s Accelerating Growth In The Real World Data Market Globally?

The growth in the Real World Data market is driven by advancements in health data infrastructure, regulatory support, and end-user demand for personalized, value-based care. Technologically, improved analytics tools, cloud scalability, and interoperability standards are enabling actionable insights from vast and diverse datasets. From an end-use perspective, biopharma, payers, and health systems are leveraging RWD to drive efficiency, optimize outcomes, and meet evolving care expectations. Increased use of digital health tools, wearables, and patient engagement platforms is generating richer datasets for analysis. Regulatory initiatives supporting RWD in decision-making and policy formulation are also boosting market credibility. As global healthcare systems transition from volume to value, the ability to derive meaningful insights from real-world evidence is becoming a key competitive differentiator.

SCOPE OF STUDY:

The report analyzes the Real World Data market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Services, Datasets); Application (Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research, Other Applications); End-Use (Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers, Government Agencies, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Aetion, Inc.
  • Atropos Health
  • BEKHealth
  • Cerner Corporation
  • Clarify Health Solutions
  • ConcertAI
  • Datavant
  • Evidera, Inc.
  • Flatiron Health, Inc.
  • HealthVerity
  • IBM Corporation
  • ICON plc
  • IQVIA Holdings Inc.
  • K2view
  • Merative
  • Mount Sinai Health System
  • Optum, Inc.
  • Palantir Technologies Inc.
  • PAREXEL International Corporation
  • SAS Institute Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Real World Data - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Accelerated Shift Toward Evidence-Based Healthcare Models Spurs Use of Real World Data
    • Increased Regulatory Acceptance of RWD in Drug Approvals and Label Expansions Drives Market Relevance
    • Rising Use of EHR, Claims, and Patient-Reported Outcomes Data Expands Data Variety
    • Growth in Value-Based Care and Health Economics Research Strengthens Demand for Real-World Evidence
    • AI and Advanced Analytics Integration Enhances Data Utility in Clinical and Commercial Strategy
    • Collaborations Between Pharma, Payers, and Tech Firms Propel RWD Platform Development
    • Decentralized Clinical Trials and Virtual Health Models Expand Demand for Real-Time Patient Data
    • Regulatory Pressure for Post-Market Surveillance and Pharmacovigilance Supports Adoption
    • Privacy Concerns and Data Governance Requirements Present Compliance Challenges
    • Global Expansion of Health Data Infrastructure Opens Regional Growth Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Real World Data Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Real World Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Real World Data by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Datasets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Datasets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Healthcare Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Healthcare Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Government Agencies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Government Agencies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharmaceutical & Medical Device Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Pharmaceutical & Medical Device Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Healthcare Payers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Healthcare Payers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Drug Development & Approvals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Drug Development & Approvals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Market Access & Reimbursement / Coverage Decisions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Market Access & Reimbursement / Coverage Decisions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Post-Market Surveillance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Post-Market Surveillance by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Clinical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Clinical Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 28: USA Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • JAPAN
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • CHINA
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 46: China Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • EUROPE
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Real World Data by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Real World Data by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • FRANCE
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 60: France Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • GERMANY
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 78: UK Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030

IV. COMPETITION